Doxepin, the small molecule drug, serves as a cogent therapeutic agent, targeting both the norepinephrine transporter (NET) and serotonin transporter subtype 5 (SERT-5).

Fenofibrate, the small molecule drug, possesses a unique ability to target the peroxisome proliferator-activated receptor alpha (PPARα) as an agonist.

Simvastatin, a diminutive molecular entity, functions as an HMG-CoA reductase enzyme inhibitor, which is accountable for the synthesis of cholesterol in the hepatic tissue.

Glipizide, a small yet powerful drug from Pfizer Inc., effectively combats hyperglycemia and type 2 diabetes.

Hydrocortisone, a diminutive yet powerful molecule, is renowned for its aptitude to function as a glucocorticoid receptor (GR) agonist, thereby stimulating the GR.

Budesonide, a small molecule drug with a strong ability to bind to the glucocorticoid receptor (GR) as an agonist, was approved as early as 1981 and has been on the market for more than 40 years.

Prazosin, a minuscule molecule drug, exhibits antagonistic properties towards α1A-AR, α1B-AR, and α1D-AR receptors.

Digoxin, a small molecule, is known for inhibiting Na/K-ATPase, increasing intracellular calcium, and thus enhancing heart function.

Phenazopyridine, a diminutive molecule, serves primarily as an analgesic agent for urinary tract pain.

Sodium bicarbonate, approved for medical use since 1981, continues to be a versatile treatment for many conditions.

Triamcinolone, a synthetic corticosteroid, acts as a potent glucocorticoid receptor agonist, mainly used to treat autoimmune diseases such as psoriasis, lupus, and rheumatoid arthritis.

Nifedipine is a small molecule drug that acts as a blocker of voltage-dependent calcium channels (VDCCs), which are involved in the regulation of calcium ions in the cardiovascular system.